Table 5.

Incremental cost-effectiveness ratio for scenario analysis.

Parameters	2012–2025		2026–2031
Scenario analysis	Government perspective	Societal perspective	Government perspective	Societal perspective
Low disease incidence	119	101	680	655
Low efficacy	193	177	1,079	1,058
Low treatment cost	92	88	533	529
Low vaccine coverage	89	73	530	510
Base case scenario	89	73	530	510
High vaccine coverage	89	73	530	510
High treatment cost	89	73	530	510
High efficacy	89	73	530	510
High disease incidence rate	89	73	530	510
Probabilistic sensitivity analysis
Median ICER	91	73	550	524
Lower 95%	68	45	433	405
Upper 95%	144	128	747	716